What is NGX Bio?
NGX Bio operates as a marketplace for genomic sequencing services, founded by Stanford professors who identified a critical need for accurate, fast, and affordable sequencing solutions. The company addresses market inefficiencies by acting as a central hub that monitors quality, negotiates pricing, and ensures capacity across various sequencing facilities. This model allows researchers to access high-quality data without the risks associated with selecting individual providers. In 2019, NGX Bio was acquired by Admera Health, further expanding its offerings to encompass a comprehensive suite of NGS-based products, services, and solutions through an extensive partner network.
How much funding has NGX Bio raised?
NGX Bio has raised a total of $3M across 1 funding round:
Private Equity
$3M
Private Equity (2017): $3M with participation from Berkeley Angel Network, 180 Degree Capital Corp, Third Kind Venture Capital, Band, and Lateral Capital
Key Investors in NGX Bio
Berkeley Angel Network
The Berkeley Angel Network is an investment collective of UC Berkeley alumni, faculty, and former faculty, focused on supporting entrepreneurship and fostering an investor community. They prioritize companies with ties to UC Berkeley technology or founders.
180 Degree Capital Corp
180 Degree Capital Corp. is an investment firm that focuses on undervalued micro-cap stocks, employing a constructive activist strategy to enhance shareholder value. They aim to generate returns by actively engaging with management teams of companies in out-of-favor industries.
Third Kind Venture Capital
Third Kind Venture Capital is an early-stage venture capital firm established in 2010, specializing in investments within the consumer internet, software, and financial services sectors. The firm is headquartered in New York City.
What's next for NGX Bio?
The substantial enterprise-level funding and recent strategic investment indicate a strong market validation for NGX Bio's innovative approach to genomic sequencing. This capital infusion is expected to fuel further development of its marketplace technology, enhance its service offerings, and expand its reach within the life sciences and biotechnology industries. The company is poised to solidify its position as a leader in providing accessible and high-quality genomic data solutions, potentially driving advancements in research and clinical applications.
See full NGX Bio company page
